L
Lei Shi
Researcher at Chinese PLA General Hospital
Publications - 26
Citations - 9522
Lei Shi is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Pneumonia & Hepatocellular carcinoma. The author has an hindex of 11, co-authored 24 publications receiving 6790 citations.
Papers
More filters
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.
Journal ArticleDOI
Liver injury in COVID-19: management and challenges.
Chao Zhang,Lei Shi,Fu-Sheng Wang +2 more
Journal ArticleDOI
Single-cell landscape of immunological responses in patients with COVID-19.
Ji Yuan Zhang,Xiang Ming Wang,Xudong Xing,Zhe Xu,Chao Zhang,Jin-Wen Song,Xing Fan,Peng Xia,Jun Liang Fu,Si Yu Wang,Ruo Nan Xu,Xiao Peng Dai,Lei Shi,Lei Huang,Tian Jun Jiang,Ming Shi,Yuxia Zhang,Alimuddin Zumla,Alimuddin Zumla,Markus Maeurer,Fan Bai,Fu-Sheng Wang +21 more
TL;DR: The single-cell transcriptional landscape of moderate, severe and convalescent cases of patients with COVID-19 describes the dynamic nature of immune responses during disease progression, and shows a deranged interferon response, profound immune exhaustion with skewed T cell receptor repertoire and broad T cell expansion.
Journal ArticleDOI
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Fanping Meng,Ruonan Xu,Siyu Wang,Zhe Xu,Chao Zhang,Yuanyuan Li,Tao Yang,Lei Shi,Junliang Fu,Tian-Jun Jiang,Lei Huang,Peng Zhao,Xin Yuan,Xing Fan,Ji-Yuan Zhang,Jin-Wen Song,Dawei Zhang,Yan-Mei Jiao,Limin Liu,Chun-Bao Zhou,Markus Maeurer,Alimuddin Zumla,Alimuddin Zumla,Ming Shi,Fu-Sheng Wang +24 more
TL;DR: Evaluated data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated, and phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC- MSCs to reduce deaths and improve long- term treatment outcomes.
Journal ArticleDOI
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
Lei Shi,Hai Huang,Xuechun Lu,Xiaoyan Yan,Xiaojing Jiang,Ruonan Xu,Siyu Wang,Chao Zhang,Xin Yuan,Zhe Xu,Lei Huang,Junliang Fu,Yuanyuan Li,Zhang Yu,Wei-Qi Yao,Tianyi Liu,Jin-Wen Song,Liangliang Sun,Fan Yang,Xin Zhang,Bo Zhang,Ming Shi,Fanping Meng,Yanning Song,Yongpei Yu,Jiqiu Wen,Qi Li,Qing Mao,Markus Maeurer,Alimuddin Zumla,Chen Yao,Wei-Fen Xie,Fu-Sheng Wang +32 more
TL;DR: Wang et al. as mentioned in this paper performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on their phase 1 data.